Have you been diagnosed with obesity? The good news is that there are steps you can take to lose weight. Based on your BMI range and other health factors, your doctor may recommend one or more of the following options.
If you have a BMI at or above 25, the first line of obesity treatment is lifestyle therapy. This means diet and exercise, but also counselling and other types of personal support to help you make lifestyle changes and overcome barriers to weight loss1. Unfortunately, while lifestyle therapy helps many people with obesity to lose weight, it is not always sufficient to maintain weight loss over time2,3.
If your BMI is 30 or above, or if you have obesity-related complications, and do not achieve significant weight loss with lifestyle therapy alone, then your doctor may recommend anti-obesity medication as additional treatment4. Anti-obesity medications can help you to lose weight by reducing your appetite and changing the way your body absorbs food5.
Weight loss surgery
Weight loss surgery – also known as bariatric surgery – is a third line of treatment for obesity management. Your doctor may recommended this option if your BMI is 40 or above and you also have obesity-related health complications.?
Even small improvements in your weight can make a big difference to your health and general wellbeing. A weight loss of 5% can reduce your risk of developing obesity-related complications and enhance your quality of life.
Despite the fact that there is now a better understanding of the science behind obesity, medical treatment options remain limited. At Novo Nordisk, our scientists are working to develop new medicines to help people manage this serious chronic disease.
DISEASE EXPERIENCE EXPERT PANELS
At Novo Nordisk, we consider people living with serious chronic diseases to be experts. That's why we invite them to become members of our Disease Experience Expert Panels (DEEPs). DEEP members are able to provide disease-specific insights and advice based on real-world experiences. This input guides us as we work to develop better treatments and meaningful support for people living with chronic diseases worldwide.
Obesity perspectives is a blog where members of Novo Nordisk's Disease Experience Expert Panels (DEEPs) share their personal perspectives on living with obesity. Our bloggers offer thought-provoking opinions, advice and encouragement for every step of the obesity journey.
Volunteer to take part in a Novo Nordisk clinical trial, and you’ll be helping our researchers discover more about new treatments that could one day benefit millions of people worldwide. You’ll also learn about managing your own weight and health.
1AACE/ACE. Clinical practice guidelines for comprehensive
medical care of patients with obesity - executive summary. Available
MB). Last accessed: March 2018
2Mann T, Tomiyama AJ, Westling E, et al. Medicare's search for effective obesity treatments: diets are not the answer. The American Psychologist. 2007; 62:220–233
3Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014; 129:S102-138.
4Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014; 129:S102-138.
5Mingfang L, B C. Pharmacotherapy for obesity British Journal of Clinical Pharmacology 2009; 68:804–810.
6Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine. 2002; 346:393–403.
7Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011; 34:1481–1486.
8Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011; 34:1481–1486.
9Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. The American Journal of Clinical Nutrition. 1992; 56:320–328.
10Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011; 34:1481–1486.
11Riddle DL, PW S. Body Weight Changes and Corresponding Changes in Pain and Function in Persons With Symptomatic Knee Osteoarthritis: A Cohort Study. Arthritis Care & Research 2013; 65:15–22.
12Tuomilehto H, Seppa J, Uusitupa M, et al. The impact of weight reduction in the prevention of the progression of obstructive sleep apnea: an explanatory analysis of a 5-year observational follow-up trial. Sleep Medicine 2014; 15:329–335.
13Foster GD, Borradaile KE, Sanders MH, et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Archives of Internal Medicine. 2009; 169:1619–1626.
14Warkentin LM, Das D, Majumdar SR, et al. The effect of weight loss on health-related quality of life: systematic review and meta-analysis of randomized trials. Obes Rev. 2014; 15:169-182.